Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valganciclovir for CMV in allogeneic HSCT
NCT00386412Phase 2Completed
- Sponsor
- Fundación PETHEMA
- Start
- Nov 2005
- Primary completion
- Sep 2009
- Countries
- 1
01
Overview
Phase 2, open-label trial of valganciclovir in cytomegalovirus infection (CMV), sponsored by Fundación PETHEMA. Primary endpoint: Valganciclovir efficacy in advance treatment of CMV at 1 year. Started Nov 2005; status: completed.
02
Drugs
valganciclovir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT00386412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00386412.